Search Drug Information, Interactions, Images, Dosage & Side Effects

Aspirin, cilostazol exert similar effects on white matter changes in cerebral small vessel disease 27 Nov 2021
The progression of white matter changes in cerebral small vessel disease does not seem to be different between aspirin- and cilostazol-treated patients, a study has found.

Statins help preserve liver function in chronic liver disease

27 Nov 2021

Tonsillectomy may lower risk of psoriasis

27 Nov 2021

Spinal anaesthesia no better than general anaesthesia for hip surgery

27 Nov 2021

Patients with vitiligo at risk of hearing loss

27 Nov 2021

Hidradenitis suppurativa bidirectionally linked to atopic dermatitis

27 Nov 2021

Dietary gluten restriction unlikely to prevent digestive system cancers

27 Nov 2021

Music plus abdominal vibrations safe but ineffective against musculoskeletal pain in older adults

27 Nov 2021

PRO-C3 levels, ADAPT score accurately detect fibrosis in NAFLD

27 Nov 2021

Does COVID-19 vaccine effectiveness wane over time?

26 Nov 2021

Cardiac events more common in isolated vs systemic cardiac sarcoidosis

26 Nov 2021

EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF 18 Nov 2021;
Heart failure with preserved ejection fraction (HFpEF) represents a significant unmet medical need. The EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the hotline session of the 2021 ESC Virtual Congress, the main results of the EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal investigator of the study, and heart failure specialist at Charité Berlin, Germany.

NOACs in nonvalvular atrial fibrillation with multimorbidity: Where does apixaban stand?

02 Nov 2021

Fighting oxidation: new insights in pathogenesis and management of atopic dermatitis

01 Nov 2021

Preparedness attenuates COVID-19 risk among people with diabetes and obesity

30 Oct 2021

Lixiana

Contents : Edoxaban tosilate

Indications/Uses : Prevention of stroke & systemic embolism in adult patients w/ nonvalvular atrial fibrillation (NVAF) w/ ≥1 risk factors eg, CHF, HTN, age ≥75 yr, DM, prior stroke or transient ischaemic attack. Treatment of deep vein thrombosis (DVT) & pulmonary embolism (PE) in adults. Prevention of recurrent DVT & PE in adults.

Cresemba

Contents : Isavuconazole

Indications/Uses : Invasive aspergillosis; mucormycosis in patients for whom amphotericin B is inappropriate.

Cabometyx

Contents : Cabozantinib

Indications/Uses : Advanced renal cell carcinoma in treatment-naive adults w/ intermediate or poor risk; adults following prior vascular endothelial growth factor-targeted therapy. Monotherapy for hepatocellular carcinoma in adults who have previously been treated w/ sorafenib.

Cavsamir

Contents : Sevelamer carbonate

Indications/Uses : Control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis, or chronic kidney disease (CKD) not on dialysis w/ serum P ≥1.78 mmol/L.